|
Horizon Pharma Public Limited Company () is a specialty pharmaceutical company that develops and markets medicine through its subsidiaries in the United States. The company was founded in 2005 and is based in Dublin, Ireland. The product base of the company is mainly for the treatment of arthritis, pain and inflammatory diseases. ==Business== The company lead product base includes DUEXIS and RAYOS. Outside the United States, RAYOS is also known as LODOTRA. The company has cooperated with American Gastroenterological Association (AGA) Institute to launch a program named “Connect to Protect” which aims to help physicians and patients better understand non-steroidal anti-inflammatory drug (NSAID) risks. The program is planned to promote communications between physicians and patients about NASAID and gastrointestinal ulcer. In March 2014, the company completed the acquisition of Vidara Therapeutics International through a merge valued at about $660 million. In October 2014, the company acquired the U.S. sales and marketing rights to the osteoarthritis drug Pennsaid from Nuvo Research for $45 million.〔(【引用サイトリンク】title=Horizon Pharma Picks Up Nuvo's Osteoarthritis Pain Drug Pennsaid 2% - GEN News Highlights - GEN )〕 In March 2015, the company acquired Hyperion Therapeutics for $1.1 billion, increasing Horizons orphan disease drug portfolio.〔(【引用サイトリンク】title=Horizon Pharma to Acquire Hyperion Therapeutics for $1.1B )〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Horizon Pharma」の詳細全文を読む スポンサード リンク
|